Intratumoral Injection of Anlotinib Hydrogel Combined With Radiotherapy Reduces Hypoxia in Lewis Lung Carcinoma Xenografts: Assessment by Micro Fluorine-18-fluoromisonidazole Positron Emission Tomography/Computed Tomography Hypoxia Imaging

Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells

(2019) Lijun Liang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Synergistic effect and reduced toxicity by intratumoral injection of cytarabine-loaded hyaluronic acid hydrogel conjugates combined with radiotherapy on lung cancer

(2019) Juan Tang et al.   INVESTIGATIONAL NEW DRUGS

Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma

(2019) Gangyang Wang et al.   INTERNATIONAL JOURNAL OF CANCER

Radiotherapy boost in patients with hypoxic lesions identified by 18F-FMISO PET/CT in non-small-cell lung carcinoma: can we expect a better survival outcome without toxicity? [RTEP5 long-term follow-up]

(2019) Pierre Vera et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species

(2018) Chen-chun Zhong et al.   ACTA PHARMACOLOGICA SINICA

Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor

(2018) Chengying Xie et al.   CANCER SCIENCE

Dosimetry study of 18F-FMISO + PET/CT hypoxia imaging guidance on intensity-modulated radiation therapy for non-small cell lung cancer

(2018) H. Li et al.   Clinical & Translational Oncology

Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients With Refractory Metastatic Soft Tissue Sarcoma

(2018) Yihebali Chi et al.   CLINICAL CANCER RESEARCH

18F-FDG PET intensity correlates with a hypoxic gene signature and other oncogenic abnormalities in operable non-small cell lung cancer

(2018) Brendan T. Heiden et al.   PLoS One

Anlotinib induces hepatocellular carcinoma apoptosis and inhibits proliferation via Erk and Akt pathway

(2018) Chao He et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Hypoxia promotes acquisition of aggressive phenotypes in human malignant mesothelioma

(2018) Myung-Chul Kim et al.   BMC CANCER

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Antitumor effects of anlotinib in thyroid cancer

(2018) Xianhui Ruan et al.   ENDOCRINE-RELATED CANCER

Anlotinib for the Treatment of Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer

(2018) Yongkun Sun et al.   THYROID

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer

(2018) Baohui Han et al.   JAMA Oncology

Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for non-small cell lung cancer therapy

(2018) Jun Lu et al.   EUROPEAN RESPIRATORY JOURNAL

Transformative hyaluronic acid-based active targeting supramolecular nanoplatform improve long circulation and enhance cellular uptake in cancer therapy

(2018) Lu Zhong et al.   Acta Pharmaceutica Sinica B

[18F]Fluoromisonidazole PET in rectal cancer

(2017) Tanuj Puri et al.   EJNMMI Research

Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors

(2016) Yongkun Sun et al.   Journal of Hematology & Oncology

The role of lymphangiogenesis and angiogenesis in tumor metastasis

(2016) Roman Paduch   CELLULAR ONCOLOGY

Lung cancer: Biology and treatment options

(2015) Hassan Lemjabbar-Alaoui et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Molecular imaging of hypoxia in non-small-cell lung cancer

(2015) Connie Yip et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Hyaluronidase-incorporated hyaluronic acid–tyramine hydrogels for the sustained release of trastuzumab

(2015) Keming Xu et al.   JOURNAL OF CONTROLLED RELEASE

Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT

(2015) Roslyn J. Francis et al.   LUNG CANCER

Chlorogenic acid inhibits hypoxia-induced angiogenesis via down-regulation of the HIF-1α/AKT pathway

(2015) Jin Ju Park et al.   CELLULAR ONCOLOGY

Synthesis of poly(glutamic acid)-tyramine hydrogel by enzyme-mediated gelation for controlled release of proteins

(2014) Zhiping Peng et al.   JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION

Hypoxia and lymphangiogenesis in tumor microenvironment and metastasis

(2013) Rui-Cheng Ji   CANCER LETTERS

Hypoxia Imaging With 18F-Fluoroerythronitroimidazole Integrated PET/CT and Immunohistochemical Studies in Non–Small Cell Lung Cancer

(2013) Man Hu et al.   CLINICAL NUCLEAR MEDICINE

Injectable hyaluronic acid-tyramine hydrogels incorporating interferon-α2a for liver cancer therapy

(2013) Keming Xu et al.   JOURNAL OF CONTROLLED RELEASE

A prospective clinical trial of tumor hypoxia imaging with 18F-fluoromisonidazole positron emission tomography and computed tomography (F-MISO PET/CT) before and during radiation therapy

(2013) Izumi Tachibana et al.   JOURNAL OF RADIATION RESEARCH

Injectable hyaluronic acid–tyramine hydrogels for the treatment of rheumatoid arthritis

(2010) K.S. Kim et al.   Acta Biomaterialia

An injectable enzymatically crosslinked hyaluronic acid–tyramine hydrogel system with independent tuning of mechanical strength and gelation rate

(2008) Fan Lee et al.   Soft Matter